None listed
Conditions
Interventions
None listed
Sponsors
Sanofi-Aventis Korea
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. = 19 years of age 2. Consecutive patients who attempt the first mobilization for ASCT between Oct 2019 and Feb 2023 3. Multiple Myeloma patients undergoing first mobilization for ASCT with G-CSF+/-chemotherapy or G-CSF + preemptive plerixafor according to cohort definition as below: a) Cohort A (G+P group): Patients who receive G-CSF and plerixafor in the first mobilization attempt b) Cohort B (G+/-chemotherapy group): - Cohort B-1 (G alone group): Patients who receive G-CSF alone in the first mobilization attempt - Cohort B-2 (G+chemotherapy group): Patients who receive G-CSF and chemotherapeutic-mobilizing agent in the first mobilization attempt Note: The chemotherapeutic-mobilizing agents include cyclophosphamide, etoposide, vinorelbine, gemcitabine, cytarabine or its combination.
Exclusion criteria
Exclusion criteria: 1. Autologous stem cell transplant eligible patients other than MM patients (ie, non Hodgkin’s lymphoma [NHL]) 2. Patients who receive G-CSF, chemotherapy and plerixafor triple combination for mobilization 3. Re-mobilizing patients with prior mobilization failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total PB CD34+ cells collected after first mobilization attempt | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients achieving =2×106 (minimum target) and =4×106 (optimal target);Mobilization failure rate% (fail to harvest minimum target);Total PB CD34+ cells collected on the first apheresis day;Successful mobilization (=2×106/kg) rate% on the first apheresis day;Days of mobilization and collection;Days of hospital stay ;Number of red blood cell (RBC) transfusions ;Number of platelet transfusions | — |
Countries
Korea, Republic of
Contacts
Public ContactKihyun Kim
Samsung Medical Center
Outcome results
None listed